RedHill Biopharma sells Talicia stake to Apotex for $18 million upfront
RDHL•RedHill sells Talicia stake to Apotex
RedHill Biopharma sold its 70% interest in Talicia to Apotex for $18 million in upfront cash.
The deal includes up to $35 million tied to worldwide net sales milestones.
Apotex gains full ownership following its earlier purchase of Cumberland’s U.S. branded business, which included the remaining 30% Talicia stake.
Proceeds to support liquidity and strategy shift
Proceeds are intended to strengthen liquidity and fund a shift toward larger commercial product opportunities in gastrointestinal medicine.
